Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 90278, held by Sun Pharm. Topiramate.
As of Nov 15, 2026, ANDA 90278 (Topiramate), held by Sun Pharm, was first approved by FDA on Mar 27, 2009, with 17 approved supplements and 0 published complete response letters.
Topiramate is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox- Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved | None posted |
| Topiramate25MG · tablet;oral | Topiramate | Discontinued |
| Topiramate50MG · tablet;oral | Topiramate | Discontinued |
| Topiramate100MG · tablet;oral | Topiramate | Discontinued |
| Topiramate200MG · tablet;oral | Topiramate | Discontinued |
| Oct 10, 2023 | Supplement 31Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 30Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 28Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 26Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 30, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 27, 2010 | Supplement 4Labeling | Approved | None posted |
| Jan 27, 2010 | Supplement 3REMS | Approved | None posted |
| Mar 27, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters